100 related articles for article (PubMed ID: 12941797)
1. Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells.
Chun KH; Lee HY; Hassan K; Khuri F; Hong WK; Lotan R
Cancer Res; 2003 Aug; 63(16):4796-800. PubMed ID: 12941797
[TBL] [Abstract][Full Text] [Related]
2. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.
Lee HY; Moon H; Chun KH; Chang YS; Hassan K; Ji L; Lotan R; Khuri FR; Hong WK
J Natl Cancer Inst; 2004 Oct; 96(20):1536-48. PubMed ID: 15494604
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer.
Han JY; Oh SH; Morgillo F; Myers JN; Kim E; Hong WK; Lee HY
J Natl Cancer Inst; 2005 Sep; 97(17):1272-86. PubMed ID: 16145048
[TBL] [Abstract][Full Text] [Related]
4. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
Smalley KS; Eisen TG
Int J Cancer; 2003 Jun; 105(2):165-75. PubMed ID: 12673674
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.
Oh SH; Jin Q; Kim ES; Khuri FR; Lee HY
Clin Cancer Res; 2008 Mar; 14(5):1581-9. PubMed ID: 18316583
[TBL] [Abstract][Full Text] [Related]
6. Farnesyltransferase inhibitor SCH66336 induces rapid phosphorylation of eukaryotic translation elongation factor 2 in head and neck squamous cell carcinoma cells.
Ren H; Tai SK; Khuri F; Chu Z; Mao L
Cancer Res; 2005 Jul; 65(13):5841-7. PubMed ID: 15994961
[TBL] [Abstract][Full Text] [Related]
7. A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer.
Oh SH; Kang JH; Kyu Woo J; Lee OH; Kim ES; Lee HY
Int J Cancer; 2012 Aug; 131(3):537-47. PubMed ID: 22113431
[TBL] [Abstract][Full Text] [Related]
8. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma.
Oh SH; Kim WY; Kim JH; Younes MN; El-Naggar AK; Myers JN; Kies M; Cohen P; Khuri F; Hong WK; Lee HY
Clin Cancer Res; 2006 Jan; 12(2):653-61. PubMed ID: 16428512
[TBL] [Abstract][Full Text] [Related]
9. Farnesyltransferase inhibition: who are the Aktors?
Bernhard EJ
Cancer Biol Ther; 2004 Nov; 3(11):1099-101. PubMed ID: 15640614
[No Abstract] [Full Text] [Related]
10. Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336).
Bruzek LM; Poynter JN; Kaufmann SH; Adjei AA
Mol Pharmacol; 2005 Aug; 68(2):477-86. PubMed ID: 15901852
[TBL] [Abstract][Full Text] [Related]
11. The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt.
Sun SY; Zhou Z; Wang R; Fu H; Khuri FR
Cancer Biol Ther; 2004 Nov; 3(11):1092-8; discussion 1099-1101. PubMed ID: 15467440
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336.
Glass TL; Liu TJ; Yung WK
Neuro Oncol; 2000 Jul; 2(3):151-8. PubMed ID: 11302335
[TBL] [Abstract][Full Text] [Related]
13. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
Peters DG; Hoover RR; Gerlach MJ; Koh EY; Zhang H; Choe K; Kirschmeier P; Bishop WR; Daley GQ
Blood; 2001 Mar; 97(5):1404-12. PubMed ID: 11222387
[TBL] [Abstract][Full Text] [Related]
14. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
[TBL] [Abstract][Full Text] [Related]
15. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.
Wang E; Casciano CN; Clement RP; Johnson WW
Cancer Res; 2001 Oct; 61(20):7525-9. PubMed ID: 11606389
[TBL] [Abstract][Full Text] [Related]
16. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt.
Woo JH; Kim YH; Choi YJ; Kim DG; Lee KS; Bae JH; Min DS; Chang JS; Jeong YJ; Lee YH; Park JW; Kwon TK
Carcinogenesis; 2003 Jul; 24(7):1199-208. PubMed ID: 12807727
[TBL] [Abstract][Full Text] [Related]
18. Activation of the PI3'K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors.
Du W; Liu A; Prendergast GC
Cancer Res; 1999 Sep; 59(17):4208-12. PubMed ID: 10485456
[TBL] [Abstract][Full Text] [Related]
19. Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells.
Mihara M; Shintani S; Kiyota A; Matsumura T; Wong DT
Int J Oncol; 2002 Jul; 21(1):95-101. PubMed ID: 12063555
[TBL] [Abstract][Full Text] [Related]
20. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
David E; Sun SY; Waller EK; Chen J; Khuri FR; Lonial S
Blood; 2005 Dec; 106(13):4322-9. PubMed ID: 16118318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
